GGrantIndex
Sort

48,018 grants matching immunotherapy

Advancing immunotherapy through cross species studies of immune cell responses and immune checkpoint inhibitor effects in dogs and humans with invasive urinary bladder cancer

$552,535
Deborah W Knapp · Purdue University · U01 · FY2023 · CA

Targeting cell regulatory states to complement MEK/autophagy inhibition in pancreatic cancer

$552,526
Kenneth P Olive · Columbia University Health Sciences · R01 · FY2024 · CA

Mechanisms of Murine Turmor Eradication by Immunotherapy

$552,495
Philip D Greenberg · University Of Washington · R01 · FY2013 · CA

Recombinant Interleukin-33 Immunotherapy for Pancreatic Cancer

$552,488
Vinod P Balachandran · Sloan-Kettering Inst Can Research · P50 · FY2023 · CA

THERAPEUTIC MANUFACTURING

$552,471
Leland H Hartwell · Fred Hutchinson Cancer Research Center · P30 · FY2012 · CA

Cutaneous T cell lymphoma: a paradigm for dissecting susceptibility and resistance to checkpoint inhibition therapy

$552,383
Christiane Querfeld · Beckman Research Institute/City Of Hope · R01 · FY2023 · CA

Characterization of Pigmentary Disorders and Melanoma Targeting

$552,336
Vincent J Hearing · Division Of Basic Sciences - Nci · ZIA · FY2009 · CA

Development of irreversible electroporation-based rational combinations to potentiate the activity of cancer immunotherapy against pancreatic ductal adenocarcinoma

$552,266
Chun Li · University Of Tx Md Anderson Can Ctr · R01 · FY2024 · CA

Integrated Discovery Pipeline for Tumor Neoantigens

$552,250
Beatriz M. Carreno · University Of Pennsylvania · R01 · FY2018 · CA

Small circular mRNA vaccines

$552,247
Guizhi Zhu · Virginia Commonwealth University · R01 · FY2023 · AI

Small circular mRNA vaccines

$552,247
Guizhi Zhu · Virginia Commonwealth University · R01 · FY2022 · AI

Identification and assessment of unconventional tumor-associated antigens as potential targets for cytotoxic T-cell based immunotherapy of cancer

$552,182
Gregory A Lizee · University Of Tx Md Anderson Can Ctr · R01 · FY2024 · CA

NIH Chronic GVHD Study Group

$552,181
Steven Pavletic · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA

Novel Computation Methods for the Analysis of Cell-Free DNA Sequence Data

$552,176
Xianghong Jasmine Zhou · University Of California Los Angeles · R01 · FY2020 · CA

Novel Computation Methods for the Analysis of Cell-Free DNA Sequence Data

$552,176
Xianghong Jasmine Zhou · University Of California Los Angeles · R01 · FY2019 · CA

Novel Computation Methods for the Analysis of Cell-Free DNA Sequence Data

$552,176
Xianghong Jasmine Zhou · University Of California Los Angeles · R01 · FY2021 · CA

Optimizing Novel Immunotherapy Combinations Targeting the Tumor Microenvironment in Canine Spontaneous Osteosarcoma

$552,171
Steven W. Dow · Colorado State University · U01 · FY2022 · CA

A deubiquitination module controls Treg adaptation to tumor microenvironment

$552,115
Deyu Fang · Northwestern University At Chicago · R01 · FY2023 · CA

Project 2: Radiation-Induced Lymphopenia: Understanding, Predictive Modeling and Developing Photon and Proton-Based Mitigation Strategies.

$552,100
Steven Hsesheng Lin · Massachusetts General Hospital · P01 · FY2022 · CA

Investigation of the role of epithelial-mesenchymal plasticity in renal cell carcinoma

$552,054
Giannicola Genovese · University Of Tx Md Anderson Can Ctr · R01 · FY2023 · CA

Re-wiring PDAC Tumor Immunity Through Dendritic Cells

$551,987
David G Denardo · Washington University · R01 · FY2021 · CA

ITIM-receptors for cancer treatment

$551,973
Chengcheng Zhang · Ut Southwestern Medical Center · R01 · FY2024 · CA

Neoadjuvant Immunotherapy with Intratumoral CPG and PD-1 Blockade in Melanoma

$551,927
Hassane M Zarour · University Of Pittsburgh At Pittsburgh · R01 · FY2021 · CA

Modulation of the tumor microenvironment with probiotic therapies

$551,862
Tal Danino · Columbia Univ New York Morningside · R01 · FY2023 · CA

Congenic Mouse Medels of Melanoma for the Characterization of Tumor Immune Responses

$551,750
Marcus W Bosenberg · Yale University · R01 · FY2017 · CA